Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Nuevolution in connection with a directed share issue
Mandate

Vinge advises Nuevolution in connection with a directed share issue

May 25, 2018

The board of directors of Nuevolution has resolved on a directed new issue of shares, whereby Nuevolution will raise proceeds of approximately SEK 110 million, before issue costs.

The share issue is directed to a number of selected Swedish and international investors, on the basis of an accelerated bookbuilding process conducted by Carnegie Investment Bank AB (publ) and Redeye AB.

Nuevolution AB (publ) is a small molecule drug discovery biotech company. The company’s shares are admitted to trading on Nasdaq First North Premier.

Vinge’s team has consisted of Dain Hård Nevonen, David Andersson, Malte Hedlund and Stephanie Stiernstedt.

Related

Vinge advises Impilo on the establishment of a continuation fund

 Vinge has advised Impilo with regulatory advice on the establishment of Impilo Orphan Drugs, a so-called continuation fund. The continuation fund will have EUR 320m in commitments and will invest in Immedica, in which KKR recently became an owner alongside Impilo.
November 15, 2024

Vinge advises Österlens Kraft economic association in connection with the sale of all shares in Österlens Kraft Fjärrvärme AB to Adven Sverige AB

 Österlens Kraft Fjärrvärme AB produces, distributes and sells district heating to the company's customers in Simrishamn.
November 14, 2024

Vinge advises Abacus Bidco Oy (which is the parent company of Accountor Software recently acquired by KKR) in the acquisition of certain subsidiaries and assets of 24SevenOffice Group AB (“24SevenOffice”)  

 24SevenOffice is a listed company (First North Stockholm) that provides modular software for accounting, ERP and business services that automate processes using AI.
November 13, 2024